MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review

Doxorubicin is a broad-spectrum chemotherapy drug applied in antitumor therapy. However, its clinical utility is limited by its fatal cardiotoxicity. Doxorubicin (DOX)-induced cardiomyopathy (DIC) begins with the first DOX dose and is characterized by being cumulative dose-dependent, and its early d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liuying Chen, Yizhou Xu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	doxorubicin microRNAs cardiotoxicity biomarkers treatment strategy Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/79f29938436f4674bd0cbca264b17b1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:79f29938436f4674bd0cbca264b17b1a
record_format	dspace
spelling	oai:doaj.org-article:79f29938436f4674bd0cbca264b17b1a2021-11-30T19:37:09ZMicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review2297-055X10.3389/fcvm.2021.740515https://doaj.org/article/79f29938436f4674bd0cbca264b17b1a2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.740515/fullhttps://doaj.org/toc/2297-055XDoxorubicin is a broad-spectrum chemotherapy drug applied in antitumor therapy. However, its clinical utility is limited by its fatal cardiotoxicity. Doxorubicin (DOX)-induced cardiomyopathy (DIC) begins with the first DOX dose and is characterized by being cumulative dose-dependent, and its early diagnosis using common detection methods is very difficult. Therefore, it is urgent to determine the underlying mechanism of DIC to construct treatment strategies for the early intervention before irreversible damage to the myocardium occurs. Growing evidence suggests that microRNAs (miRNAs) play regulatory roles in the cardiovascular system. miRNAs may be involved in DIC by acting through multiple pathways to induce cardiomyocyte injury. Recent studies have shown that the dysregulation of miRNA expression can aggravate the pathological process of DIC, including the induction of oxidative stress, apoptosis, ion channel dysfunction and microvascular dysfunction. Current findings on the roles of miRNAs in DIC have led to a wide range of studies exploring candidate miRNAs to be utilized as diagnostic biomarkers and potential therapeutic targets for DIC. In this review, we discuss frontier studies on the roles of miRNAs in DIC to better understand their functions, develop relevant applications in DIC, discuss possible reasons for the limitations of their use and speculate on innovative treatment strategies.Liuying ChenYizhou XuFrontiers Media S.A.articledoxorubicinmicroRNAscardiotoxicitybiomarkerstreatment strategyDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	doxorubicin microRNAs cardiotoxicity biomarkers treatment strategy Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	doxorubicin microRNAs cardiotoxicity biomarkers treatment strategy Diseases of the circulatory (Cardiovascular) system RC666-701 Liuying Chen Yizhou Xu MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review
description	Doxorubicin is a broad-spectrum chemotherapy drug applied in antitumor therapy. However, its clinical utility is limited by its fatal cardiotoxicity. Doxorubicin (DOX)-induced cardiomyopathy (DIC) begins with the first DOX dose and is characterized by being cumulative dose-dependent, and its early diagnosis using common detection methods is very difficult. Therefore, it is urgent to determine the underlying mechanism of DIC to construct treatment strategies for the early intervention before irreversible damage to the myocardium occurs. Growing evidence suggests that microRNAs (miRNAs) play regulatory roles in the cardiovascular system. miRNAs may be involved in DIC by acting through multiple pathways to induce cardiomyocyte injury. Recent studies have shown that the dysregulation of miRNA expression can aggravate the pathological process of DIC, including the induction of oxidative stress, apoptosis, ion channel dysfunction and microvascular dysfunction. Current findings on the roles of miRNAs in DIC have led to a wide range of studies exploring candidate miRNAs to be utilized as diagnostic biomarkers and potential therapeutic targets for DIC. In this review, we discuss frontier studies on the roles of miRNAs in DIC to better understand their functions, develop relevant applications in DIC, discuss possible reasons for the limitations of their use and speculate on innovative treatment strategies.
format	article
author	Liuying Chen Yizhou Xu
author_facet	Liuying Chen Yizhou Xu
author_sort	Liuying Chen
title	MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review
title_short	MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review
title_full	MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review
title_fullStr	MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review
title_full_unstemmed	MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review
title_sort	micrornas as biomarkers and therapeutic targets in doxorubicin-induced cardiomyopathy: a review
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/79f29938436f4674bd0cbca264b17b1a
work_keys_str_mv	AT liuyingchen micrornasasbiomarkersandtherapeutictargetsindoxorubicininducedcardiomyopathyareview AT yizhouxu micrornasasbiomarkersandtherapeutictargetsindoxorubicininducedcardiomyopathyareview
_version_	1718406273039335424

MicroRNAs as Biomarkers and Therapeutic Targets in Doxorubicin-Induced Cardiomyopathy: A Review

Ejemplares similares